Valuation: Lundbeck

Market Cap 4.41TCr 665.17Cr 590.47Cr 552.57Cr 500.84Cr 945.87Cr 64TCr 952.72Cr 6.64TCr 2.58TCr 33TCr 2.5TCr 2.44TCr 1,05200Cr P/E 2026 *
9.93x
P/E 2027 * 9.69x
Enterprise Value 4.81TCr 725.49Cr 644.02Cr 602.68Cr 546.27Cr 1.03TCr 70TCr 1.04TCr 7.24TCr 2.82TCr 36TCr 2.72TCr 2.66TCr 1,14700Cr EV / Sales 2026 *
1.86x
EV / Sales 2027 * 1.68x
Free-Float
30.74%
Yield 2026 *
3.46%
Yield 2027 * 3.12%
1 day+1.58%
1 week+1.76%
Current month+1.23%
1 month-1.70%
3 months+17.48%
6 months+26.75%
Current year+19.67%
1 week 5.51
Extreme 5.51
5.82
1 month 5.24
Extreme 5.24
5.98
Current year 4.22
Extreme 4.22
5.98
1 year 4.22
Extreme 4.22
5.98
3 years 3.12
Extreme 3.125
5.98
5 years 3.03
Extreme 3.028
10.99
10 years 3.03
Extreme 3.028
10.99
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 67 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.58%+1.76% - - 652.01Cr
+1.26%-2.29%+36.97%+104.79% 1,01900Cr
+0.73%-4.78%+35.41%+61.62% 61TCr
+0.35%+1.29%+15.86%+79.90% 47TCr
+1.72%-4.92%+59.84%+36.64% 34TCr
+0.26%+0.14%+21.29%+40.99% 34TCr
+0.60%-3.09%+10.76%+32.59% 27TCr
+1.65%-3.78%-6.03%+9.29% 24TCr
-0.09%-4.97%+36.88%+50.52% 22TCr
-0.28%-4.66%+26.99%+92.98% 18TCr
Average +0.50%-3.71%+26.44%+56.59% 40.92TCr
Weighted average by Cap. +0.06%-3.43%+29.52%+67.02%

Financials

2026 *2027 *
Net sales 2.59TCr 389.9Cr 346.11Cr 323.89Cr 293.58Cr 554.44Cr 38TCr 558.45Cr 3.89TCr 1.51TCr 19TCr 1.46TCr 1.43TCr 62TCr 2.61TCr 393.37Cr 349.19Cr 326.78Cr 296.19Cr 559.38Cr 38TCr 563.42Cr 3.92TCr 1.53TCr 19TCr 1.48TCr 1.44TCr 62TCr
Net income 456.68Cr 69Cr 61Cr 57Cr 52Cr 98Cr 6.63TCr 99Cr 686.7Cr 267.08Cr 3.38TCr 258.34Cr 252.8Cr 11TCr 461.95Cr 70Cr 62Cr 58Cr 52Cr 99Cr 6.71TCr 100Cr 694.61Cr 270.16Cr 3.42TCr 261.32Cr 255.72Cr 11TCr
Net Debt 400.29Cr 60Cr 54Cr 50Cr 45Cr 86Cr 5.82TCr 86Cr 601.9Cr 234.1Cr 2.97TCr 226.44Cr 221.59Cr 9.54TCr -18Cr -2.74Cr -2.43Cr -2.28Cr -2.06Cr -3.9Cr -264.12Cr -3.92Cr -27Cr -11Cr -134.74Cr -10Cr -10Cr -433.15Cr
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
06/26/06 €5.780 +1.58% 0
05/26/05 €5.690 +2.15% 7
02/26/02 €5.570 +0.91% 8
01/26/01 €5.520 -3.33% 1,761
30/26/30 €5.710 +0.53% 52
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
44.86DKK
Average target price
49.19DKK
Spread / Average Target
+9.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck